文献速递冠心病

PCI术后长期单药维持:氯吡格雷对比阿司匹林10年随访结果

Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial.
PubMed 文献 · Lancet · 2026-03-29

本研究对HOST-EXAM试验进行10年延长随访,纳入5438例PCI术后完成双联抗血小板治疗且无事件的患者,随机接受氯吡格雷75 mg每日一次或阿司匹林100 mg每日一次。结果支持在PCI术后慢性维持期考虑以氯吡格雷替代阿司匹林作为长期抗血小板单药治疗。

要点

  • PCI术后慢性维持期,氯吡格雷单药较阿司匹林单药主要复合终点发生率更低。
  • 氯吡格雷组血栓终点和出血终点发生率均低于阿司匹林组。
  • 两组全因死亡率无显著差异。

核心结论

  • PCI术后10年随访中,氯吡格雷单药较阿司匹林单药与更低的主要复合终点、缺血终点和出血终点发生率相关,但与全因死亡率无关。

研究设计与样本

  • 研究设计为HOST-EXAM试验的研究者发起的10年延长随访。
  • 纳入5438例PCI术后完成双联抗血小板治疗6-18个月且无临床事件的患者,随机分配至阿司匹林组(n=2728)或氯吡格雷组(n=2710)。
  • 主要分析在意向治疗人群中进行。

主要发现

  • 全因死亡率在两组间相似。

关键数值与推荐

  • 主要复合终点包括全因死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院及BARC≥3型出血。

临床怎么用

  • 对于PCI术后完成双联抗血小板治疗且无事件的患者,可考虑以氯吡格雷替代阿司匹林作为长期抗血小板单药治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term clinical outcomes of clopidogrel monotherapy versus aspirin monotherapy after percutaneous coronary intervention (PCI) remain uncertain. We conducted a 10-year follow-up of the HOST-EXAM trial to assess the very long-term effects of clopidogrel versus aspirin monotherapy in this setting. METHODS: In HOST-EXAM, patients who had completed dual antiplatelet therapy without clinical events for 6-18 months after PCI were randomly assigned to receive clopidogrel 75 mg once daily or aspirin 100 mg once daily. This study is an investigator-initiated 10-year extended follow-up of the HOST-EXAM trial. The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and Bleeding Academic Research Consortium type ≥3 bleeding. The primary analysis was done in the intention-to-treat population. The study is registered with ClinicalTrials.gov (NCT02044250) and is complete. FINDINGS: From March 26, 2014, to May 29, 2018, 5530 patients were enrolled and 5438 were randomly assigned to the aspirin group (n=2728) or the clopidogrel group (n=2710). Clinical follow-up status was ascertained on May 1, 2025, resulting in a median follow-up duration of 10·5 years (IQR 9·4-11·4) after PCI and a completion rate of 92·8%. Clopidogrel was associated with a lower rate of the primary composite endpoint than aspirin (Kaplan-Meier estimate 25·4% for the clopidogrel group vs 28·5% for the aspirin group; hazard ratio 0·86 [95% CI 0·77-0·96]; log-rank p=0·0050). Clopidogrel was also associated with a lower rate of the thrombotic endpoint (17·3% vs 20·0%; log-rank p=0·0024) and bleeding endpoint (9·1% vs 10·8%; log-rank p=0·020). All-cause mortality was similar between groups. INTERPRETATION: During 10 years of follow-up, clopidogrel monotherapy, compared with aspirin monotherapy, was associated with lower rates of the primary composite, ischaemic, and bleeding outcomes, but not all-cause mortality after PCI. These findings support consideration of clopidogrel as an alternative to aspirin for long-term antiplatelet monotherapy during the chronic maintenance phase after PCI. FUNDING: Ministry of Health & Welfare, South Korea.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Kang, Park, Yang, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial. Lancet. 2026. PMID: 41921522. doi:10.1016/S0140-6736(26)00422-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。